Medical/Pharmaceuticals
Alterity Therapeutics to Present at the 34th Annual Roth Conference
MELBOURNE, Australia and SAN FRANCISCO, March 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced thatDavid Stamler, M.D.,...
2022-03-07 20:59
2483
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia in Female Patients
SUZHOU, China, March 6, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment of 160 patients for its...
2022-03-07 08:18
3938
Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy
* Phase 2 study of PVX108 to commence in United States and Australia * Dr Robert A. Wood, professor of pediatrics at the Johns Hopkins University School of Medicine, joins Scientific Advisory Board MELBOURNE, Australia, March 4, 2022 /PRNewswire/ -- Aravax, a clinical stage biotechnology compa...
2022-03-04 21:00
3567
111, Inc. Reaches Strategic Partnership on Direct Supply with Beilin Pharmaceutical to Blaze New Trails in Digital Development of Chinese Patent Medicine
SHANGHAI, March 4, 2022 /PRNewswire/ -- On February 23, 2022, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, signed a strategic cooperation agreement on direct supply with Xi'an Beilin Pharmaceutical Co., Ltd. ("Beilin Pharmaceutical")...
2022-03-04 17:24
2571
Genome and Company announces Clinical Trial Collaboration with MSD to evaluate 'GEN-001' in combination of KEYTRUDA® (pembrolizumab) in phase 2 clinical trial in biliary tract cancer patients
SEOUL, South Korea, March 3, 2022 /PRNewswire/ -- Genome and Company (KOSDAQ: 314130, CEO∙CTO: Jisoo Pae∙Hansoo Park), a leading global microbiome anti-cancer drug development company, announced it has entered into a first Clinical Trial Collaboration and Supply Agreement (CTCSA) with MSD (a trad...
2022-03-04 09:30
2947
Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China
SHANGHAI, March 3, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that the Center for Drug Evaluation (CDE) of the National Medic...
2022-03-03 21:50
2704
I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer
SHANGHAI and GAITHERSBURG, Md., March 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the U.S. Food and Drug Administration (FDA) has gr...
2022-03-03 21:00
2291
Akeso Announces Clinical Trial Collaboration with Chipscreen Biosciences to Evaluate Cadonilimab in Combination with Chiauranib for Extensive-Stage Small-Cell Lung Cancer
HONG KONG, March 2, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwidetoday announced that it has entered into a collab...
2022-03-03 01:34
2752
Seegene appoints Richard Creager as CEO of U.S. subsidiary to bolster U.S. business
SEOUL, South Korea, March 2, 2022 /PRNewswire/ -- Seegene Inc.
2022-03-02 20:00
2040
REDCLOUD BIO ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR NEXT-GENERATION EGFR INHIBITOR H002 IN NON-SMALL CELL LUNG CANCER
* Drug Candidate Is First From Company To Enter Phase I/IIa Clinical Trial * H002 Has Potential To Overcome Resistance Driven By Various EGFR C797S-Containing Mutations in Non-Small Cell Lung Cancer SHANGHAI, March 2, 2022 /PRNewswire/ -- RedCloud Bio (the "Company"), an innovative biotech com...
2022-03-02 17:27
1591
InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of NMOSD in China
BEIJING, March 1, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib by China National Medical Products Administration (NMPA) to start ph...
2022-03-02 10:37
2763
WuXi Biologics Wins CMO Leadership Awards in All Six Core Categories for Fifth Consecutive Year
SHANGHAI, March 1, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO service company, today announced that the company has won the 2022 CMO Leadership Awards in all six core categories (i.e., capabilities, compatibility, expertise, reliability, quality and service).2022 m...
2022-03-02 10:07
2608
ImmVira's breakthrough intravenous oncolytic virus product MVR-T3011 IV completed first dosing in Phase I clinical trial in China
SHENZHEN, China, March 1, 2022 /PRNewswire/ -- Following its robust safety data in the U.S. Phase I clinical study, ImmVira announced that its global first intravenous administered oncolytic herpes simplex virus ("oHSV") product MVR-T3011 IV has completed first dosing onMarch 1, 2022 and initiate...
2022-03-02 09:07
1702
Vocera, now part of Stryker, introduces latest evolution in hands-free communication to help protect and connect healthcare workers
New Minibadge expands intuitive mobile solutions for care team collaboration and safety KALAMAZOO, Michigan, USA, March 1, 2022 /PRNewswire/ -- Vocera, now part of Stryker, a global leading medical technology company, introduced the new Minibadge, a wearable, voice-driven device that enables mobi...
2022-03-01 21:00
1868
Kintor Pharma Announces First Patient Dosing in Phase II Clinical Trial of KX-826 for Treatment of Androgenic Alopecia Patients in the US
SUZHOU, China, March 1, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in its phase II clinical trial of KX-826 ("...
2022-03-01 20:30
2482
PHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A KETOGENIC DIET ENROLLS FIRST PATIENT
SYDNEY, Feb. 28, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in combination with metformin and a ketogenic diet for the treatmen...
2022-02-28 21:00
3200
First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial
SYDNEY, Feb. 25, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has successfully treated its first participant in cohort ...
2022-02-25 22:04
3607
Daewoong Pharmaceutical Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy
SEOUL, South Korea, Feb. 25, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) announced the topline results of the phase 3 clinical trial for a triple combination therapy of Enavogliflozin, a new antidiabetic drug with the mechanism of SGLT-2 inhibitor, with Metformin and Gemigliptin. Enav...
2022-02-25 22:00
3889
Terumo and Corazon Sign Collaboration and Co-Marketing Agreement
SOMERSET, N.J., Feb. 25, 2022 /PRNewswire/ -- Terumo Health Outcomes, a division of Terumo Medical Corporation, a leading global medical device manufacturer, has signed a collaboration and co-marketing agreement with Corazon, Inc., a leader in providing consulting, recruitment, interim managemen...
2022-02-25 22:00
4251
PharmAbcine Announces Last Patient Last Visit in its Phase Ib mTNBC Combination Trial
DAEJEON, South Korea, Feb. 25, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the completion of last patient last visit in its Phase Ib combination trial for mTNBC (me...
2022-02-25 21:00
3003
Week's Top Stories
Most Reposted
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
The Philippines Sets a New Standard in Muslim-Friendly Tourism
[Picked up by 290 media titles]
2026-05-26 10:30
Agoda and Philippines Department of Tourism announce strategic partnership to promote and elevate tourism
[Picked up by 286 media titles]
2026-05-27 09:16
Consistently recognised: Infobip named a Leader in Gartner® Magic Quadrant™ for CPaaS again
[Picked up by 281 media titles]
2026-05-21 16:31
ISDN's IDI Dynamics debuts high-speed laser marker for semiconductor assembly and test (OSAT)
[Picked up by 280 media titles]
2026-05-26 08:40
Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
9207
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
8741
